Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer (Q27853180)

From Wikidata

Jump to navigation Jump to search

scientific article published on 14 July 2015

Language	Label	Description	Also known as
English	Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer	scientific article published on 14 July 2015

Statements

scholarly article

1 reference

13 November 2016

Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer (English)

1 reference

13 November 2016

phase II clinical trial

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

P A Jänne

1

0 references

I Smith

2

0 references

G McWalter

3

0 references

H Mann

4

0 references

B Dougherty

5

0 references

J Walker

6

0 references

M C M Orr

7

0 references

D R Hodgson

8

0 references

A T Shaw

9

0 references

J R Pereira

10

0 references

G Jeannin

11

0 references

J Vansteenkiste

12

0 references

C H Barrios

13

0 references

F A Franke

14

0 references

L Crinò

15

0 references

P Smith

16

0 references

language of work or name

0 references

publication date

14 July 2015

0 references

British Journal of Cancer

0 references

113

0 references

2

0 references

199-203

0 references

copyright license

Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International

30 June 2015

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4506393

20 March 2017

Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4506393

20 March 2017

A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4506393

20 March 2017

Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4506393

20 March 2017

The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4506393

20 March 2017

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4506393

20 March 2017

Prognostic impact of KRAS mutation subtypes in 677 patients with metastatic lung adenocarcinomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4506393

29 September 2017

Panel based MALDI-TOF tumour profiling is a sensitive method for detecting mutations in clinical non small cell lung cancer tumour

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4506393

29 September 2017

Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4506393

29 September 2017

KRAS mutations as prognostic and predictive markers in non-small cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4506393

29 September 2017

The BATTLE trial: personalizing therapy for lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4506393

29 September 2017

Different types of K-Ras mutations could affect drug sensitivity and tumour behaviour in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2015.215

21 January 2018

Identifiers

10.1038/BJC.2015.215

0 references

Dimensions Publication ID

0 references

1 reference

13 November 2016

1 reference

13 November 2016

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q27853180&oldid=2175349169"